PMGC Holdings Inc. (ELAB) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, PMGC reported revenue of $590,084. Net income was -$7.7M (a -1313.0% net margin). Gross margin was 31.4% and operating margin was -1166.3%. Operating activities generated -$5.9M of cash, leaving -$6.4M of free cash flow. At fiscal year end, PMGC held $12.9M in total assets against $5.0M in total liabilities.
Open the full interactive PMGC financials → Quarterly statements, key ratios, valuation history and price charts.
PMGC Key Stats
| Share Price | $2.96 |
|---|---|
| Market Cap | $1.4M |
| 52-Week Range | $2.96 – $2,167.20 |
| Shares Outstanding | 487,650 (basic, 2026 Q2) |
PMGC Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $1.7M | $0 | $590,084 |
| Cost of Goods Sold | $578,015 | — | $404,770 |
| Gross Profit | $1.1M | — | $185,314 |
| Operating Income | -$3.8M | — | -$6.9M |
| Pre-Tax Income | -$4.3M | -$6.2M | -$7.7M |
| Income Tax | — | — | $30,972 |
| Net Income | -$4.3M | -$6.2M | -$7.7M |
| Diluted EPS | -$471578.95 | — | — |
PMGC Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $285,948 | $304,136 | $681,994 | $1.3M |
| Net Income | -$2.6M | -$3.0M | -$5.0M | -$2.9M |
PMGC Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash & Equivalents | — | $4.0M | — |
| Current Assets | $4.9M | $6.1M | $6.9M |
| Total Assets | $5.2M | $9.0M | $12.9M |
| Current Liabilities | $1.3M | $1.8M | $3.9M |
| Total Long-Term Debt | — | $200,000 | $170,000 |
| Total Liabilities | $1.4M | $2.3M | $5.0M |
| Shareholders' Equity | $3.8M | $6.7M | $7.8M |
PMGC Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | -$4.6M | -$5.5M | -$5.9M |
| Cash From Investing | -$11,191 | -$610,564 | -$2.8M |
| Cash From Financing | $6.7M | $6.8M | $10.1M |
| Free Cash Flow | — | -$5.5M | -$6.4M |
Figures from PMGC's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full PMGC financials page for every line item.
PMGC Company Profile
| Ticker | ELAB |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Newport Beach, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001840563 |
Frequently Asked Questions
What was PMGC's revenue in fiscal 2025?
PMGC (ELAB) reported revenue of $590,084 for fiscal 2025.
What is PMGC's annual revenue history?
PMGC's annual revenue by fiscal year: 2023: $1.7M; 2024: $0; 2025: $590,084.
What was PMGC's net income in fiscal 2025?
PMGC reported net income of -$7.7M for fiscal 2025.
How much free cash flow did PMGC generate in fiscal 2025?
PMGC generated -$6.4M of free cash flow in fiscal 2025.
What was PMGC's revenue last quarter?
In its most recent reported quarter (2026 Q2), PMGC reported revenue of $1.3M.
How much debt does PMGC have?
PMGC reported $170,000 of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of PMGC are outstanding?
PMGC reported a weighted average of 487,650 basic shares outstanding in 2026 Q2.
What is PMGC's market cap?
Based on its latest closing price, PMGC (ELAB) has a market capitalization of about $1.4M.
When does PMGC's fiscal year end?
PMGC's fiscal year end, as registered with the SEC, is December 31.
Where is PMGC headquartered?
PMGC lists its business address in Newport Beach, California in its SEC filings.